The Trump administration chimed in again for the 3rd time in history last week, asking the public to weigh in on global Marijuana reform. He urged the masses to submit comments to help inform the U.S. on the direction of the rescheduling of Cannabis. It was only a month ago when the World Health Organization formally recommended that the drug and it’s derivatives be reclassified under international consensus, and it looks like they have some strong support from the Red White and Blue.
The FDA is interested in seeing the public response and will take all feedback into consideration when preparing for their meeting with the United Nations Commission on Narcotics, being held in Vienna, Austria later this year. It is an exciting time as the nations leading medical and research bodies, as well as law-abiding citizens, can all have a say in the reform of the substance and have their voices heard.
The vote could take place as soon as this month as to whether THC and relative compounds will hold true to their initial 1961 treaty classifications. As times progress it is encouraging to see political leaders take interest in updating convention.
“The evidence presented to the Committee did not indicate that the Cannabis plant and Cannabis resin were particularly liable to produce ill-effects similar to the effects of the other substances in Schedule IV of the 1961 Single Convention on Narcotic Drugs,” WHO determined. “In addition, preparations of Cannabis have shown therapeutic potential for treatment of pain and other medical conditions such as epilepsy and spasticity associated with multiple sclerosis.”
It’s tough for large bodies and institutions to re-recognize something that they may have been wrong about for years, however, the unlocked medical potential seems intriguing to the WHO. They would still, however, maintain a level of compliance while promoting the legalization of the plant in different nations. Their outlook has the possibility of creating a rippling effect across the globe as a whole.
WHO also wants to discuss the other popular cannabidiol CBD, a non-intoxicating Marijuana component increasingly used for medical benefits. They too claim it should not fall under international restrictions at all.
“Cannabidiol is found in Cannabis and Cannabis resin but does not have psychoactive properties and has no potential for abuse and no potential to produce dependence,” WHO’s report found. “It does not have significant ill-effects. Cannabidiol has been shown to be effective in the management of certain treatment-resistant, childhood-onset epilepsy disorders.”
The Bureau of the 62nd Commission is considering a postponed date for voting on the Cannabis-related recommendations. The new vote might fall on December, or the 63rd session of the Commission on Narcotic Drugs, March 2020. This might feel like a canyon of time between now and when we hear their final recommendations, however with such a delicate global matter, the WHO and UN not only want to make sure all relevant parties are present but that all of the public comments are heard in the process. These are very exciting times indeed for the future of the Cannabis plant as it sits in the limelight.
Stay connected to the story! Happy Investing.
Read Other Celebrity Cannabis Articles
The Cannabis Investor is a leading media outlet for Cannabis investment opportunities and breaking industry news.
Join our text message list:
USA: Text potstocks to 313131 to join
CDN: Text potstocks to 393939 to join
Join our email list here: http://eepurl.com/bUSa71
Follow The Cannabis Investor on Social Media